- Home
- NEWT vs FHTX Comparison
NEWT vs FHTX Comparison
Compare NEWT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- FHTX
- Stock Information
- Founded
- NEWT 1998
- FHTX 2015
- Country
- NEWT United States
- FHTX United States
- Employees
- NEWT 591
- FHTX N/A
- Industry
- NEWT Major Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NEWT Finance
- FHTX Health Care
- Exchange
- NEWT Nasdaq
- FHTX Nasdaq
- Market Cap
- NEWT 316.7M
- FHTX 278.1M
- IPO Year
- NEWT N/A
- FHTX 2020
- Fundamental
- Price
- NEWT $12.03
- FHTX $4.80
- Analyst Decision
- NEWT Hold
- FHTX Strong Buy
- Analyst Count
- NEWT 4
- FHTX 6
- Target Price
- NEWT $13.00
- FHTX $11.33
- AVG Volume (30 Days)
- NEWT 163.1K
- FHTX 86.4K
- Earning Date
- NEWT 11-05-2025
- FHTX 11-03-2025
- Dividend Yield
- NEWT 6.41%
- FHTX N/A
- EPS Growth
- NEWT 21.23
- FHTX N/A
- EPS
- NEWT 2.01
- FHTX N/A
- Revenue
- NEWT $364,004,000.00
- FHTX $24,173,000.00
- Revenue This Year
- NEWT N/A
- FHTX $43.75
- Revenue Next Year
- NEWT $12.73
- FHTX $1.27
- P/E Ratio
- NEWT $5.89
- FHTX N/A
- Revenue Growth
- NEWT 20.91
- FHTX N/A
- 52 Week Low
- NEWT $9.12
- FHTX $2.95
- 52 Week High
- NEWT $15.49
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NEWT 52.65
- FHTX 41.47
- Support Level
- NEWT $11.44
- FHTX $5.14
- Resistance Level
- NEWT $11.77
- FHTX $5.58
- Average True Range (ATR)
- NEWT 0.30
- FHTX 0.35
- MACD
- NEWT -0.04
- FHTX -0.06
- Stochastic Oscillator
- NEWT 57.28
- FHTX 0.94
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.